Recurrent Ovarian Carcinoma Completed Phase 2 Trials for Sirolimus (DB00877)

Back to Recurrent Ovarian Carcinoma
IndicationStatusPhase
DBCOND0030000 (Recurrent Ovarian Carcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01010126Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell CancerTreatment